1. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae:
epidemiology and prevention. Clin Infect Dis. 2011;53:60-7.
2. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae.
Emerg Infect Dis. 2011;17:1791-8.
3. Sekar R, Mythreyee M, Srivani S, Sivakumaran D, Lallitha S, Saranya S. Carbapenem-resistant
Enterobacteriaceae in Pediatric Bloodstream Infections in Rural Southern India. Indian
Pediatr. 2017;54:1021-4.
4. Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, et al. Antimicrobial-resistant
pathogens associated with healthcare-associated infections: Summary of data reported
to the National Healthcare Safety Network at the Centers for Disease Control and Prevention,
2011–2014. Infect Control Hosp Epidemiol. 2016; 37:1288-1301.
5. Morrill HJ, Pogue JM, Kaye KS, LaPlante KL. Treatment Options for Carbapenem-Resistant
Enterobacteriaceae Infections. Open Forum Infect Dis. 2015;2:ofv050.
6. Logan LK. Carbapenem-resistant enterobacteriaceae: an emerging problem in children.
Clin Infect Dis. 2012;55:852-9.
7. Singh NP, Choudhury DD, Gupta K, Rai S, Batra P, Manchanda V, et al. Predictors
for gut colonization of carbapenem-resistant Enterobacteriaceae in neonates in a neonatal
intensive care unit. Am J Infect Control. 2018;46:e31-e35.
8. Limbago BM, Rasheed JK, Anderson KF, Zhu W, Kitchel B, Watz N, et al. IMP-producing
carbapenem-resistant Klebsiella pneumoniae in the United States. J Clin Microbiol.
2011;49:4239-45.
9. Hsu AJ, Tamma PD. Treatment of multidrug-resistant Gram-negative infections in
children. Clin Infect Dis. 2014;58:1439-48.
10. Stillwell T, Green M, Barbadora K, Ferrelli JG, Roberts TL, Weissman SJ, et al.
Outbreak of KPC-3 Producing Carbapenem-Resistant Klebsiella pneumoniae in a US Pediatric
Hospital. J Pediatric Infect Dis Soc. 2015;4:330-8.
11. Drew RJ, Turton JF, Hill RL, Livermore DM, Woodford N, Paulus S, et al. Emergence
of carbapenem-resistant Enterobacteriaceae in a UK paediatric hospital. J Hosp Infect.
2013;84:300-4.
12. Chiotos K, Tamma PD, Flett KB, Naumann M, Karandikar MV, Bilker WB, et al. Multicenter
Study of the Risk Factors for Colonization or Infection with Carbapenem-Resistant
Enterobacteriaceae in Children. Antimicrob Agents Chemother. 2017;61. pii: e01440-17.
13. Institute CLS. Performance Standards for antimicrobial susceptibility testing;
Twenty-eighth Informational Supplement, M100. CLSI: Wayne (PA); 2018.
14. Logan LK, Hujer AM, Marshall SH, Domitrovic TN, Rudin SD, Zheng X, et al. Analysis
of β-Lactamase Resistance Determinants in Enterobacteriaceae from Chicago Children:
a Multicenter Survey. Antimicrob Agents Chemother. 2016;60:3462-9.
15. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, et al.
Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority
of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56:2108-13.
16. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al.
Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae
carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect
Dis. 2012; 55:943-50.
17. Nabarro LEB, Shankar C, Pragasam AK, Mathew G, Jeyaseelan V, Veeraraghavan B,
et al. Clinical and Bacterial Risk Factors for Mortality in Children With Carbapenem-resistant
Enterobacteriaceae Bloodstream Infections in India. Pediatr Infect Dis J. 2017;36:e161-e166.
18. Oteo J, Hernandez-Almaraz JL, Gil-Anton J, Vindel A, Fernandez S, Bautista V,
et al. Outbreak of vim-1-carbapenemase-producing Enterobacter cloacae in a pediatric
intensive care unit. Pediatr Infect Dis J. 2010;29:1144-6.
19. Herruzo R, Ruiz G, Perez-Blanco V, Gallego S, Mora E, Vizcaino MJ, et al. Bla-OXA48
gene microorganisms outbreak, in a tertiary Children's Hospital, Over 3 years (2012-2014):
Case Report. Medicine (Baltimore). 2017;96:e7665.
20. Zerr DM, Weissman SJ, Zhou C, Kronman MP, Adler AL, Berry JE, et al. The Molecular
and Clinical Epidemiology of Extended-Spectrum Cephalosporin- and Carbapenem-Resistant
Enterobacteriaceae at 4 US Pediatric Hospitals. J Pediatric Infect Dis Soc. 2017;6:366-75.
21. Kehl SC, Dowzicky MJ. Global assessment of antimicrobial susceptibility among
Gram-negative organisms collected from pediatric patients between 2004 and 2012: results
from the Tigecycline Evaluation and Surveillance Trial. J Clin Microbiol. 2015;53:1286-93.
22. Colombo S, Scolfaro C, Calitri C, Denina M, Carraro F, De Intinis G, et al. Carbapenemase-producing
enterobacteriaceae (CPE) in the pediatric setting: results from an 18-month survey.
Infect Control Hosp Epidemiol. 2014;35:599-601.
23. Purdy J, Jouve S, Yan JL, Balter I, Dartois N, Cooper CA, et al. Pharmacokinetics
and safety profile of tigecycline in children aged 8 to 11 years with selected serious
infections: a multicenter, open-label, ascending-dose study. Clin Ther. 2012;34:496-507.e1.
24. Chiotos K, Han JH, Tamma PD. Carbapenem-Resistant Enterobacteriaceae Infections
in Children. Curr Infect Dis Rep. 2016;18:2.
25. Nour I, Eldegla HE, Nasef N, Shouman B, Abdel-Hady H, Shabaan AE. Risk factors
and clinical outcomes for carbapenem-resistant Gram-negative late-onset sepsis in
a neonatal intensive care unit. J Hosp Infect. 2017;97:52-8.